

## PrescQIPP work plan 2025-7 (two-year rolling work plan)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027
Covert administration	Update on LPS as still not come into force in place of DoLS. Consider SMR as first step in process. Consider any new references. Consider adding CQC recommendations for which information to record. Note CQC not in NI. Also differentiate between refusal and request for deferred dose. <a href="https://www.cqc.org.uk/guidance-providers/adult-social-care/covert-administration-medicines">https://www.cqc.org.uk/guidance-providers/adult-social-care/covert-administration-medicines</a>	C								
Dental products on FP10	Update to include advice for patients with cancer (caries prevention in head and neck cancer) and prescribing of artificial saliva products. Include when it is appropriate to prescribe toothpastes, e.g. oncology or should this be hospital supply? Include pathway guidance and discussion on availability of dental care.  Guidance around what dental products GPs should/should not prescribe and potential liability, e.g. metronidazole suppositories in LDA patient	N								
NSAIDs	Update to include cost comparison charts. Could be refreshed and republished.	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter									
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027		
Point of care testing	Update - consider community pharmacy testing and clear directions regarding genomic testing program	N										
Vitamins and minerals (including Vitamin D)	Review of cost effective options based on current prices. Guidance for care homes. Update post Covid 19. Place in therapy for the new once monthly vitamin D preparation. Bariatric surgery guidance needed. Cost comparison charts. Update with NICE B12 guidance. Link to bariatric surgery bulletin. Cover what is commissioned by NHSE: <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-275-vitamin-d/">https://www.prescqipp.info/our-resources/bulletins/bulletin-275-vitamin-d/</a> <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-296-vitamins-and-minerals/">https://www.prescqipp.info/our-resources/bulletins/bulletin-296-vitamins-and-minerals/</a>	C										
Oral nutritional supplements	Review prices and cost effective options. Update in line with National NHSE workstream. Review recipe books if needed. Add cost comparison charts. Switching between ONS products, deprescribing reviews, appropriate use, potential patient cohorts, searches. <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-261-oral-nutritional-supplements/">https://www.prescqipp.info/our-resources/bulletins/bulletin-261-oral-nutritional-supplements/</a>	C										
PROP-List	Consider new devices that could be included, such as mucus clearing devices. Scope other areas of limited clinical value. PROP list - consider separating suggested alternatives from main document and linked to direct alternatives on the table. <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-235-prop-list/">https://www.prescqipp.info/our-resources/bulletins/bulletin-235-prop-list/</a>	N										

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027
Neuropathic pain	<p>Include NI position, especially regarding pregabalin and include more information to discourage the use of tramadol/place in therapy/risks, etc. safety advice regrading gabapentinoids. Include review of lidocaine plasters.</p> <p><a href="https://www.britishpainsociety.org/mediacentre/news/bps-position-statement-on-lidocaine-plasters/">https://www.britishpainsociety.org/mediacentre/news/bps-position-statement-on-lidocaine-plasters/</a></p> <p><a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-216-neuropathic-pain/">https://www.prescqipp.info/our-resources/bulletins/bulletin-216-neuropathic-pain/</a></p>	C								
UTIs - Prevention, recognition and management	<p>Update in line with national guidance. Include community pharmacy first schemes. Methenamine (Hiprex) to be included in light of ALTAR trial (NICE reviewing). Educational slideset to include community pharmacy service and any key messages for them around, e.g. AMS.</p> <p><a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-277-prevention-recognition-and-management-of-utis/">https://www.prescqipp.info/our-resources/bulletins/bulletin-277-prevention-recognition-and-management-of-utis/</a> Add information about pharmacy first</p> <p><a href="https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-services/pharmacy-first/">https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-services/pharmacy-first/</a></p>	C								
Menopause	<p>NICE guidance Menopause: identification and management published 7 November 2024. Need advice on off-label use of products and use in breast cancer patients. Testosterone guidance - monitoring and dose adjustment.</p> <p><a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-299-menopause/">https://www.prescqipp.info/our-resources/bulletins/bulletin-299-menopause/</a></p>	C								

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027
Acute Kidney Injury and CKD	Will be combined with the Implementing NICE guidance for CKD and AKI, which will need updating in 2025/6 <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-260-acute-kidney-injury-aki-sick-day-guidance/">https://www.prescqipp.info/our-resources/bulletins/bulletin-260-acute-kidney-injury-aki-sick-day-guidance/</a> <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-281-implementing-nice-guidance-in-ckd-and-aki/">https://www.prescqipp.info/our-resources/bulletins/bulletin-281-implementing-nice-guidance-in-ckd-and-aki/</a>	C								
Maximising prescribing resources - update	Update bulletin 327 maximising prescribing resources spreadsheet to include key current SGLT2 NICE TA cost pressures that are not currently included, i.e. SGLT2s for CKD; and SGLT2s for heart failure. Include updated SGLT2 health economic data for purposes of promoting best value from meds worthy of increased spend/prescribing to justify prescribing cost pressures. <a href="https://prescqipp.info/our-resources/bulletins/bulletin-327-maximising-prescribing-resources/">https://prescqipp.info/our-resources/bulletins/bulletin-327-maximising-prescribing-resources/</a>	N								
Treatment of migraine	Implementation of NICE guidance and evaluation of new treatments for migraine. Draft pathway development. Appropriate education tools for clinicians	C								
COPD	Update to bulletin 283 COPD ( <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-283-copd/">https://www.prescqipp.info/our-resources/bulletins/bulletin-283-copd/</a> ) to include updated NICE/GOLD guidelines, and other national guidance such as <a href="https://awttc.nhs.wales/files/guidelines-and-pils/all-wales-copd-management-and-prescribing-guideline-pdf/">https://awttc.nhs.wales/files/guidelines-and-pils/all-wales-copd-management-and-prescribing-guideline-pdf/</a>  Include steroid inhaler use and triple therapy indications as well as stepping down where not indicated. Prescribing and monitoring requirements of theophylline and where this is indicated.	C								

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027
Commissioning high cost drugs and devices	<p>Update to bulletin 309. Commissioning high cost drugs and devices</p> <p><a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-309-commissioning-of-high-cost-drugs-and-devices/">https://www.prescqipp.info/our-resources/bulletins/bulletin-309-commissioning-of-high-cost-drugs-and-devices/</a></p> <p>Update needed based on new contract and research funding changes, provider selection regime etc. We are awaiting the 2025/26 NHS PS, noting that the contracting round is already in progress and is expected to conclude by the end of March 2025.</p>	N								
Medication and falls	<p>Update to bulletin 300 Medication and falls.</p> <p><a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-300-medication-and-falls/">https://www.prescqipp.info/our-resources/bulletins/bulletin-300-medication-and-falls/</a></p> <p>Highlight this is part of NHSE MOO. ACB burden and cognitive impairment - link to bone protection with bone sparing agent if possible</p>	C								
ADHD	<p>Update to bulletin 302 ADHD</p> <p><a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-302-prescribing-in-adhd/">https://www.prescqipp.info/our-resources/bulletins/bulletin-302-prescribing-in-adhd/</a></p> <p>Include discussion about the Right to Choose issues and medicines shortages. There may be some national guidance due in 2025/26</p>	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter									
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027		
Amiodarone and dronedarone	Update to bulletin 248 Amiodarone and Dronedarone <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-248-amiodarone-and-dronedarone/">https://www.prescqipp.info/our-resources/bulletins/bulletin-248-amiodarone-and-dronedarone/</a> Include discussion about amiodarone and diltiazem interaction and support for shared care.	C										
LHRH agonists in prostate cancer	Update to bulletin 257 LHRH agonists in prostate cancer. <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-257-lhrh-agonists-in-prostate-cancer/">https://www.prescqipp.info/our-resources/bulletins/bulletin-257-lhrh-agonists-in-prostate-cancer/</a> Discussion about their use across a plethora of indications. Potential savings opportunities. Include staladex and relugolix potential savings opportunities. Case studies/examples/ learning from ICBs that have successfully completed a switch to lower cost and less frequently admin triptorelin. Place in therapy for 6 month injections and payments practices receive.	C										
Probiotics	Update to bulletin 262 Probiotics <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-262-probiotics/">https://www.prescqipp.info/our-resources/bulletins/bulletin-262-probiotics/</a> Include discussion on current trend on media around improving gut microbiome which should be part of self care.	C										

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027
Care homes medicines optimisation	Update to bulletin 279 Care homes medicines optimisation. <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-279-care-homes-medicine-optimisation/">https://www.prescqipp.info/our-resources/bulletins/bulletin-279-care-homes-medicine-optimisation/</a> Include updates to DES requirements and also EHCH. Incorporate the ONE Devon advice sheets as tools with this resource <a href="https://prescqipp.info/our-resources/webkits/care-homes/">https://prescqipp.info/our-resources/webkits/care-homes/</a>	N								
Prescribing, ordering and receiving medicines in care homes	Update to bulletin 291 Prescribing, ordering and receiving medicines in care homes. <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-291-prescribing-ordering-and-receiving-medicines-in-care-homes/">https://www.prescqipp.info/our-resources/bulletins/bulletin-291-prescribing-ordering-and-receiving-medicines-in-care-homes/</a> Add information for oxygen cylinders, anaphylaxis etc. Update to include NI, Wales and Scotland guidance too. Link to RPS toolkit.	N								
Medicines administration in care homes	Update to bulletin 293 Medicines administration in care homes. <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-293-medicines-administration-in-care-homes/">https://www.prescqipp.info/our-resources/bulletins/bulletin-293-medicines-administration-in-care-homes/</a> NI stated there is no equality act in NI so make relevant for NI.	N								
Fentanyl	Update to bulletin 285 Fentanyl <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-285-fentanyl/">https://www.prescqipp.info/our-resources/bulletins/bulletin-285-fentanyl/</a>	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027
Antipsychotic drugs	<p>Update to bulletin 286 Antipsychotic drugs.  <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-286-antipsychotic-drugs/">https://www.prescqipp.info/our-resources/bulletins/bulletin-286-antipsychotic-drugs/</a></p> <p>Elements of this document do not apply in NI, e.g. they do not have SCG arrangements in place for prescribing of antipsychotics. Link to overmedication resources. Review prescribing in patients on multiple antipsychotics.</p>	C								
Sunscreens	<p>Update to bulletin 289 Sunscreens.  <a href="https://www.prescqipp.info/our-resources/bulletins/bulletin-289-sunscreens/">https://www.prescqipp.info/our-resources/bulletins/bulletin-289-sunscreens/</a></p> <p>Update along with additional info about who can be prescribed and what quantity is recommended, e.g. some policies recommending 200ml per month, as prescribing is only for face, neck and hands - other parts of the body should be covered up with clothing or sunscreen purchased by the patient. Include NI data and increase emphasis on sun avoidance, e.g. Australian messaging re slip slap slop seek slide. Further information on the ACBS indications to help decide if patients which patients suitable for prescribing. List of drugs where sunscreens may be needed. Sunscreens in schools.</p>	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)



Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027
Branded generic medicines	<p>Update to bulletin 290 Branded generic medicines.  <a href="https://www.prescgipp.info/our-resources/bulletins/bulletin-290-branded-generic-medicines/">https://www.prescgipp.info/our-resources/bulletins/bulletin-290-branded-generic-medicines/</a></p> <p>Add information on changes in discount deduction. How to deal with inconsistencies eg MHRA recommendation to brand prescribe MR meds and BNF saying not necessary for many. Consider AWMMSG position statement.  <a href="https://awttc.nhs.wales/files/guidelines-and-pils/prescribing-of-branded-generics-in-nhs-wales-position-statement-pdf/">https://awttc.nhs.wales/files/guidelines-and-pils/prescribing-of-branded-generics-in-nhs-wales-position-statement-pdf/</a></p>	N								
Repeat prescriptions	<p>Update to bulletin 292 Repeat prescriptions.  <a href="https://www.prescgipp.info/our-resources/bulletins/bulletin-292-repeat-prescriptions/">https://www.prescgipp.info/our-resources/bulletins/bulletin-292-repeat-prescriptions/</a></p> <p>Incorporate links to RPS toolkit. Draft standard policy which can be adapted locally.</p>	N								
Rubefaciants	<p>Update to bulletin 287 Rubefaciants.  <a href="https://www.prescgipp.info/our-resources/bulletins/bulletin-287-rubefaciants/">https://www.prescgipp.info/our-resources/bulletins/bulletin-287-rubefaciants/</a></p> <p>Cost comparison charts, capsaisin and drug shortages.</p>	C								
GLP-1 mimetic quantities	<p>Update to hot topic GLP-1 Mimetics  <a href="https://www.prescgipp.info/our-resources/webkits/hot-topics/">https://www.prescgipp.info/our-resources/webkits/hot-topics/</a></p> <p>Update with new treatments (Mounjaro) and discontinued drugs.</p>	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027
Topiramate in women of child bearing potential	Some useful interpretation of the NatPSA on use of topiramate in women of child bearing potential. As most prescribing is initiated by primary care (for migraine prophylaxis) some FAQs and useful guidance on how to implement.	C								
Medication reviews	A practical guide to undertaking medication reviews for new/ training practice pharmacists. Link to the pharmacy technician medication review bulletin 259.  Tools to support undertaking good quality medication reviews/ structured medication reviews	C								
Addressing health inequalities	Tools and resources to support addressing health inequalities.	N								
Right to choose	Update hot topic resource and do a full QA to convert into a bulletin. Include new info regarding NCA contracts etc.	N								
Patient decision aids	Bulletin on Patient Decision Aids highlighting the important role they can play with patients when discussing prescribing of medication. The bulletin could also highlight the resources available, e.g. GP Evidence, NICE shared decision making resource etc.	N								
Introduction to working in primary care for pharmacy professionals	Introduction to prescribing and medicines optimisation in primary care and working in general practice/PCNs. This resources is aimed at pharmacists and pharmacy technicians new to this area.	S								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter									
			Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026	Q1 Apr - Jun 2026	Q2 Jul - Sep 2026	Q3 Oct - Dec 2026	Q4 Jan to Mar 2027		
GP Clinical system training	Update the resources on practice systems for EMIS & S1 as these are quite a few years old. Add training on adding, removing of meds, sending letters and text messages via AccuRx. Add Skills training around journal entries and patient access. What considerations (legal and best practice) do Meds Opt teams need to make.  Note the clinical system providers no longer want to provide the training so doing this will depend on us being able to find suitable trainers.	S										
Excel training	New course on excel upskilling for medicines optimisation teams to update previous recording which was done in 2016.	S										
Urinary incontinence	Implementation of NICE guidance on urinary incontinence. Update on anticholinergic burden of the medicines used into the brief. New evidence etc	C										
Pharmacogenomics	Pharmacogenomic testing in primary care and how this will allow for tailoring of individual treatments. Progress on pharmacogenetic testing pilots in general practice and potential future tests.	C										

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)